These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 8549384)

  • 1. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical evaluation of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections.
    Kawai T
    Drugs; 1995; 49 Suppl 2():416-7. PubMed ID: 8549383
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral levofloxacin 600 mg and 300 mg daily doses in difficult-to-treat respiratory infections.
    Shishido H; Furukawa K; Nagai H; Kawakami K; Kono H
    Drugs; 1995; 49 Suppl 2():433-5. PubMed ID: 8549391
    [No Abstract]   [Full Text] [Related]  

  • 4. [Levofloxacin in the treatment of respiratory infections].
    Iakovlev SV; Iakovlev VP
    Antibiot Khimioter; 2002; 47(8):32-42. PubMed ID: 12515095
    [No Abstract]   [Full Text] [Related]  

  • 5. [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].
    Nakamori Y; Tsuboi E; Narui K; Nakatani T; Nakata K; Sugi H
    Jpn J Antibiot; 1992 May; 45(5):539-47. PubMed ID: 1512940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections.
    Sato A; Ogawa H; Iwata M; Ono T; Yasuda K; Nagayama M; Shirai T; Shirai M; Ida M; Suda T
    Drugs; 1995; 49 Suppl 2():428-9. PubMed ID: 8549388
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative study of ofloxacin twice and three times daily in the treatment of respiratory tract infections.
    Sawae Y; Ninomiya K; Takaki K; Shimono N; Misumi H; Okada K
    Drugs; 1995; 49 Suppl 2():430-2. PubMed ID: 8549390
    [No Abstract]   [Full Text] [Related]  

  • 8. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 9. Levofloxacin in patients with severe respiratory tract infection.
    Odagiri S
    Drugs; 1995; 49 Suppl 2():426-7. PubMed ID: 8549387
    [No Abstract]   [Full Text] [Related]  

  • 10. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory tract penetration of quinolone antimicrobials: a case in study.
    Ritrovato CA; Deeter RG
    Pharmacotherapy; 1991; 11(1):38-49. PubMed ID: 2020610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of ofloxacin in acute exacerbations of chronic respiratory disease.
    Watanabe K; Yoshida M; Ishibashi T; Yamada H; Kido M; Hirose T; Maeda F; Matsuzaki Y
    Drugs; 1995; 49 Suppl 2():448-50. PubMed ID: 8549396
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.
    Burgmann H; Mayer B; Lukas A; Kumbein F; Oberbauer R
    Wien Med Wochenschr; 2003; 153(7-8):156-62. PubMed ID: 12764869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin.
    Norrby SR
    Expert Opin Pharmacother; 1999 Nov; 1(1):109-19. PubMed ID: 11249554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New generations of quinolones: with particular attention to levofloxacin.
    Ambrose PG; Owens RC; Quintiliani R; Nightingale CH
    Conn Med; 1997 May; 61(5):269-72. PubMed ID: 9197076
    [No Abstract]   [Full Text] [Related]  

  • 16. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
    Langtry HD; Lamb HM
    Drugs; 1998 Sep; 56(3):487-515. PubMed ID: 9777318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The present and future of levofloxacin in the treatment of respiratory infections].
    García-Rodríguez JA; Muñoz Bellido JL; Alonso Manzanares MA; Gutiérrez Zufiaurre MN
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():53-8. PubMed ID: 10563113
    [No Abstract]   [Full Text] [Related]  

  • 18. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC
    Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitory effect of ofloxacin on acute exacerbations of chronic respiratory tract infections in comparison with erythromycin.
    Kawahara S; Watanabe Y; Matsuka Y; Sato T; Takahashi K
    Drugs; 1995; 49 Suppl 2():414-5. PubMed ID: 8549382
    [No Abstract]   [Full Text] [Related]  

  • 20. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.
    Sowinski KM; Lucksiri A; Kays MB; Scott MK; Mueller BA; Hamburger RJ
    Am J Kidney Dis; 2003 Aug; 42(2):342-9. PubMed ID: 12900817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.